Sign in
Taking peopleNo phase

How optic nerve swelling changes after steroid treatment in giant cell arteritis

Tracks optic nerve swelling after steroids in giant cell arteritis.

Key facts

Who runs it
Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal
Where
Canada1 site in 1 countryChoose a country to see its sites
Trial code
Registry title
Early Temporal Dynamics of Optic Nerve Sheath Diameter After Therapy in GCA
Status
Recruiting
People taking part
60 people, planned
Started
1 May 2026
Expected to end
1 May 2029
Type of study
Observational
Treatments tested
  • Optic Nerve Sheath Ultrasound
  • Temporal artery ultrasound
  • Bloodwork : CRP and ESR
Record updated
21 October 2026

Who can take part

The trial is looking for adults with newly diagnosed giant cell arteritis (GCA) who are already in the SONIC-GCA study. Participants have repeated eye ultrasound scans and blood tests during their first 2 months of standard treatment.

Age
50 Years and older
Sex
All sexes
Disease stage
Newly diagnosed GCA, confirmed by the standard GCA check at the start of SONIC-GCA. The first optic nerve ultrasound in SONIC-GCA must be done.
Earlier treatment
Steroids (glucocorticoids) for ≤ 48 hours and ≤ 160 mg prednisone-equivalent at most before the start of the study.
Main reasons for not taking part
  • Taking part at the same time in a blinded drug trial
  • Not enrolled in SONIC-GCA
  • Not able or willing to give written consent
  • Not willing to follow the intensive visit schedule
Show the full registry criteria (5)Hide the full registry criteria

Who can take part

  • Participants must be enrolled in SONIC-GCA and must have:; completed the baseline optic nerve sheath ultrasound; confirmed GCA as determined by the baseline standardized GCA assessment in SONIC-GCA
  • Exposure to glucocorticoids for ≤ 48 hours and ≤ 160 mg prednisone-equivalent before baseline
  • Ability and willingness to provide written informed consent
  • Agreement to complete the SONIC-TIME intensive follow-up schedule

Who cannot take part

  • Concurrent participation in a blinded interventional pharmaceutical clinical trial

Eligibility questionnaire

From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Age

This trial is currently available in Canada.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Giant cell arteritis (GCA) is an inflammatory disease of large and medium arteries that can cause irreversible vision loss. Glucocorticoids (GCs) rapidly suppress inflammation, but diagnostic imaging tests such as temporal artery ultrasound or biopsy often become falsely negative within days of treatment. The optic nerve sheath diameter (ONSD), measurable by ocular ultrasound, reflects perineural edema and may serve as a quantitative biomarker of ocular inflammation in GCA.

Read full original descriptionShow less

The SONIC-TIME study (Early Temporal Dynamics of Optic Nerve Sheath Diameter After Glucocorticoid Therapy in Giant Cell Arteritis) is a single-center, prospective observational substudy embedded within SONIC-GCA (NCT05749094) at Hôpital du Sacré-Cœur de Montréal. It aims to characterize how rapidly ONSD decreases after GC initiation and how this trajectory relates to cumulative GC exposure, intravenous methylprednisolone, and early use of steroid-sparing therapies.

Sixty participants with newly diagnosed GCA will undergo serial optic nerve sheath ultrasound, blood tests (CRP, ESR), and when feasible, temporal artery ultrasound over the first two months of therapy (Days 3, 7, 10, 14, 21, 28, and Month 2). No experimental treatments are given; all participants receive standard-of-care therapy.

The primary objective is to quantify the percent change in mean ONSD from baseline to Day 28. Secondary objectives include modeling ONSD change over time, assessing associations with cumulative steroid dose and inflammatory markers, and estimating the time to normalization below the SONIC-GCA cutoff. Findings will define the optimal imaging window and refine the diagnostic and monitoring role of optic nerve ultrasound in GCA.

The group in the trial

  • GCA group

    Patients with new-onset GCA who completed the SONIC-GCA (main study) baseline visit and who received 48 hours or less of glucocorticoids and less or equal to 160mg of oral prednisone equivalent. Study visits : Baseline, then days 3, 7, 10, 14, 21, 28, and Month 2

    Treatment: Optic Nerve Sheath Ultrasound, Temporal artery ultrasound, and Bloodwork : CRP and ESR

Next steps

For your doctor

Doctor ask sheet

A PDF for your doctor: what this trial tests, who can take part, and 1 eligibility question with room for answers and notes.

Download the PDF

PDF, US Letter, 1 to 2 pages. A4 size

For the study team

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Early Temporal Dynamics of Optic Nerve Sheath Diameter After Glucocorticoid Therapy in Giant Cell Arteritis
Plain-language title
How optic nerve swelling changes after steroid treatment in giant cell arteritisGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 15 November 2026.
Criteria questions
Built from NCT07508514, who can take part
Record updated
21 October 2026